臺灣博碩士論文加值系統

中文摘要
1-芐基-3-(5'-羥甲基-2'-呋喃基)吲唑(YC-1)是本實驗室首次合成的一種新型抗血小板藥物，由於其生物活性特異且廣泛，因此，著者擬合成一系列YC-1之5-甲氧基衍生物並測試其生物活性。
以甲基 5-(3-甲氧基苯醯基)-2-呋喃酯(1)為起始物質與芐基聯胺反應產生E-及Z-型異構物的混合物(2)。將此混合物於低溫下，與四醋酸鉛於二氯甲烷中進行反應後，再加入三氟化硼參與反應，進而加熱即可形成所預期的關鍵化合物甲基5-(1-芐基-5-甲氧基-1H-吲唑-3-基)-2-呋喃酯(4)。
以甲基5-(1-芐基-5-甲氧基-1H-吲唑-3-基)-2-呋喃酯(4)作為合成酯類(8a—8d)、醯胺類(9a—9h)及胺基酸甲酯類(10a—10f)之起始物，所合成之化合物之藥理活性的篩選試驗仍在測試中。

Abstract
1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1) was first synthesized in our laboratory as a novel antiplatelet agent. Encouraged by the initial results, a series of 5-methoxy derivatives of YC-1 analogues were synthesized and examined for their biological activities.
The starting material methyl 5-(3-methoxybenzoyl)-2-furoate (1) was treated with benzylhydrazine to yield a mixture of E- and Z-form isomers 2. The hydrazone was then treated with lead tetraacetate in dichloromethane at low temperature, then boron trifluoride etherate was added and the mixture heated to form the expected key intermediate ：methyl 5-(1-benzyl-5-methoxy-1H-indazol-3-yl)-2-furoate (4).
Starting from methyl 5-(1-benzyl-5-methoxy-1H-indazol-3-yl) -2-furoate (4), various esters 8a—8d、amides 9a—9h and amino acid methyl esters 10a—10f were synthesized，biological evaluation of the synthesized compounds are currently under investigation.

目 錄
中文摘要
英文摘要
第一章 緒論
第一節 YC-1相關資料
I.YC-1之研究概況………..…………………...……...………….…1
II.YC-1之生物活性及作用機轉.…………………………...……...1
III.YC-1之功能性作用(functional effects)及可能的臨床用途….……………………………………………………………..3
第二節 血小板(platelet)之生理及病理角色……………….……...…5
第三節 吲唑類(indazole)化合物之合成方法……………………..8第四節 研究動機與目的……………………………………………11
第二章 結果與討論
第一節 化學合成與解析……………………………….…….……..12
第二節 生物活性…………...……………………………………….69
第三章 結論………………………………………………………….70
第四章 實驗部分
第一節 試藥與溶媒…………………………………………….…...71
第二節 重要儀器與實驗材料……………………………..….…….73
第三節 化合物之製備……………………………………….……...75
第四節 藥理試驗方法
I.抗血小板凝集活性試驗……………………………..………....101
II.抗血管增生之活性試驗………………………………………102
III.細胞致毒活性試驗…………………………………………...103
參考文獻……………………………………………………………..104
圖譜…………………………………………………………………...109

參考文獻
1. Ko, F. N., Wu, C. C., Kuo, S. C., Lee, F. Y., Teng, C. M., YC-1, A novel activator of platelet guanylate cyclase. Blood. 84(12): 4226-4233, 1994.
2. Wu, C. C., Ko, F. N., Kuo, S. C., Lee, F. Y., Teng, C. M., YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. British Journal of Pharmacology. 116(3): 1973-1978, 1995.
3. Friebe, A., Schultz, G., Koesling, D., Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO Journal. 15(24): 6863-6868, 1996.
4. Friebe, A., Mullershausen, F., Smolenski, A., Walter, U., Schultz, G., Koesling, D., YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Molecular Pharmacology. 54(6): 962-967, 1998.
5. Russwurm, M., Mergia, E., Mullershausen, F., Koesling, D., Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. Journal of Biological Chemistry. 277(28): 24883-24888, 2002.
6. Bellamy, T. C., Garthwaite, J., Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells. British Journal of Pharmacology. 136(1): 95-103, 2002.
7. Rothermund, L., Friebe, A., Paul, M., Koesling, D., Kreutz, R., Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. British Journal of Pharmacology. 130(2):205-8, 2000.
8. Galle, J., Zabel, U., Hubner, U., Hatzelmann, A., Wagner, B., Wanner, C., Schmidt, H. H., Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. British Journal of Pharmacology. 127(1):195-203, 1999.
9. Mullershausen, F., Friebe, A., Feil, R., Thompson, W.J.,. Hofmann,. F., Koesling, D., Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. Journal of Cell Biology. 160(5):719-27, 2003.
10. Friebe, A., Koesling, D., Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Molecular Pharmacology. 53(1): 123-127, 1998.
11. Koesling, D., Modulators of soluble guanylyl cyclase. Naunyn-Schmiedebergs Archives of Pharmacology. 358(1): 123-126, 1998.
12. Stone, J. R., Marletta, M. A., Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chemistry & Biology. 5(5): 255-261, 1998.
13. Stasch, J. P., Schmidt, P., Alonso-Alija, C., Apeler, H., Dembowsky, K., Haerter, M., Heil, M., Minuth, T., Perzborn, E., Pleiss, U., Schramm, M., Schroeder, W., Schroder, H., Stahl, E., Steinke, W., Wunder, F., NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. British Journal of Pharmacology. 136(5): 773-783, 2002.
14. Lee, F. Y., Lien, J. C., Huang, L. J., Huang, T. M., Tsai, S. C., Teng, C. M., Wu, C. C., Cheng, F. C., Kuo, S. C., Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl) indazole analogues as novel antiplatelet agents. Journal of Medicinal Chemistry. 44(22): 3746-3749, 2001.
15. Wegener, J. W., Nawrath, H., Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. European Journal of Pharmacology. 323(1): 89-91, 1997.
16. Mulsch, A., Bauersachs, J., Schafer, A., Stasch, J. P., Kast, R., Busse, R., Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. British Journal of Pharmacology. 120(4): 681-689, 1997.
17. Tulis, D. A., Bohl, Masters, K. S., Lipke, E. A., Schiesser, R. L., Evans, A. J., Peyton, K. J., Durante, W., West, J. L., Schafer, A. I., YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochemical & Biophysical Research Communications. 291(4): 1014-1021, 2002.
18. Brioni, J. D., Nakane, M., Hsieh, G. C., Moreland, R. B., Kolasa, T., Sullivan, J. P., Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. International Journal of Impotence Research. 14(1): 8-14, 2002.
19. Mizusawa, H., Hedlund, P., Brioni, J. D., Sullivan, J. P., Andersson, K. E., Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. Journal of Urology. 167(5): 2276-2281, 2002.
20. Nakane, M., Hsieh, G., Miller, L. N., Chang, R., Terranova, M. A., Moreland, R. B., Kolasa, T., Brioni, J. D., Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. International Journal of Impotence Research. 14(2): 121-127, 2002.
21. Mulsch, A., Bauersachs, J., Schafer, A., Stasch, J. P., Kast, R., Busse, R., Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. British Journal of Pharmacology. 120(4):681-9, 1997.
22. Tantini, B., Flamigni, F., Pignatti, C., Stefanelli, C., Fattori, M., Facchini, A., Giordano, E., Clo, C., Caldarera, C. M., Polyamines, NO and cGMP mediate stimulation of DNA synthesis by tumor necrosis factor and lipopolysaccharide in chick embryo cardiomyocytes. Cardiovascular Research. 49(2): 408-416, 2001.
23. Schmidt, K., Schrammel, A., Koesling, D., Mayer, B., Molecular Mechanisms Involved in Synergistic Activation of Soluble Guanylyl Cyclase by YC-1 and Nitric Oxide in Endothelial Cells. Molecular Phamacology. 59(2):220-4, 2001.
24. Wang, J. P., Chang, L. C., Huang, L. J., Kuo, S. C., Inhibition of extracellular Ca2+ entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils. British Journal of Pharmacology.62(6): 679-684, 2001.
25. Wang, J. P., Chang, L. C., Raung, S. L., Hsu, M. F., Huang, L. J., Kuo, S. C., Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms. British Journal of Pharmacology.63(4): 577-585, 2002.
26. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S., Park, J. W., YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute. 95(7): 516-525, 2003.
27. Lien, J. C., Lee, F. Y., Huang, L. J., Pan, S. L., Guh, J. H., Teng, C. M., Kuo, S. C., 1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1) derivatives as novel inhibitors against sodium nitroprusside-induced apoptosis. Journal of Medicinal Chemistry. 45(23): 4947-4949, 2002.
28. Murray, R. K., Granner, D. K., Mayes, P. A., Rodwell, V. W., Harper’s Biochemistry, 24th ed, Prentice-Hall International, INC London, 707-731, 1996.
29. Gonzalez, E. R., Antiplatelet therapy in atherosclerotic cardiovascular disease. Clinical Therapeutics. 20 Suppl B:B18-41, 1998.
30. Baumgartner, H. R.,. Muggli, R.,. Tschopp, T. B., Turitto, V. T., Platelet adhesion, release and aggregation in flowing blood: effects of surface properties and platelet function. Thrombosis & Haemostasis. 35(1):124-38, 1976 Feb 29.
31. Malmsten, C., Hamberg, M., Svensson, J., Samuelsson, B., Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency. Proceedings of the National Academy of Sciences of the United States of America. 72(4):1446-50, 1975 Apr.
32. Coller, B. S., Antiplatelet agents in the prevention and therapy of thrombosis. Annual Review of Medicine. 43:171-80, 1992.
33. Coller, B. S., Indazoles and condensed types. In A. Weissberger ed. : The chemistry of heterocyclic compounds; Pyrazoles, pyrazolines, pyrazolidines, indazoles and condensed rings. Part 3., 289-382, 1967
34. Gladstone, WAF Norman, R.O.C., J. Chem. Soc., 3048-3050, 1965
35. Yashina, S., Tanaka, A., Kuo, S.C., Yakugaku Zashi., 97, 955-961, 1997
36. Hannig, E., Kollmorgen, C., Geipel, I., The preparation of some derivatives of 5-methylindazole-3-carboxylic acid. Pharmazie. 28(11):720-3, 1973 Nov-Dec.
37. Hannig, E., Kollmorgen, C., Dressel, M.., Various derivatives of 1-benzyl-6-aminoindazole. Pharmazie. 29(10-11):685-7, 1974 Oct-Nov.
38. Ina, S., Inoue, S., Noguchi, I., Facile, I., N-heterocyclic compounds synthesis of 5,6-dialkoxy-2-aryl-2H-indazoles (author's transl). Yakugaku Zasshi - Journal of the Pharmaceutical Society of Japan. 95(10):1245-9, 1975 Oct.
39. Corsi, G., Palazzo, G., 1-Halobenzyl-1H-indazole-3-carboxylic acids. A new class of antispermatogenic agents. Journal of Medicinal Chemistry. 19(6):778-83, 1976 Jun.
40. Bistocchi, G. A., De, Meo, G., Pedini, M.,. Ricci, A., Brouilhet, H., Boucherie S., Rabaud, M., Jacquignon, P., N1-substituted 1H-indazole-3-ethyl carboxylates and 1H-indazole-3-hydroxamic acids. Farmaco - Edizione Scientifica. 36(5):315-33, 1981.
41. Conway, G. A., Loeffler, L. J., Hall, I. H., Synthesis and antitumor evaluation of selected 5,6-disubstituted 1(2)H-indazole-4,7-diones. Journal of Medicinal Chemistry. 26(6):876-84, 1983.
42. Cecchi, L., Melani, F., Palazzino, G., Filacchioni, G., Pyrrolnitrin analogues. X. Synthesis and biological activity of 1-chlorophenyl-3- or 5-nitrophenyl-pyrazole-4-carboxylic acids. Farmaco - Edizione Scientifica. 39(11):953-62, 1984.
43. Mosti, L., Menozzi, G., Schenone, P., Molinario, L., Conte, F., Montanario, C., Marmoe, E., Acetic acids bearing the 1-phenyl-1H-indazole nucleus with analgesic and antiinflammatory activity. Farmaco - Edizione Scientifica. 43(10):763-74, 1988.
44. Mosti, L., Menozzi, G., Schenone, P., Cervo, D., Esposito, G., Marmo, E., 4-Substituted 1-phenyl-1H-indazoles with analgesic, antiinflammatory, antipyretic and local anesthetic activities. Farmaco. 45(4):415-29, 1990.
45. Robertson, D. W., Bloomquist, W., Cohen, M. L., Reid, L. R., Schenck, K., Wong, D. T., Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carbo xamide, a useful radioligand for 5HT3 receptors. Journal of Medicinal Chemistry. 33(12):3176-81, 1990.
46. Wrzeciono, U., Linkowska, E., Majewska, K., Gzella, A., Stochla, K., Synthesis and anti-inflammatory activity of some indazole derivatives. 36. Azoles. Pharmazie. 48(8):582-4, 1993.
47. Perni, R. B., Wentland, M. P., Huang, J. I., Powles R. G., Aldous, S., Klingbeil, K. M., Peverly, A. D., Robinson, R. G., Corbett, T. H., Jones, J. L., Mattes, K. C., Rake, J. B., Coughlin, S. A., Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzo thiopyranoindazole derivatives. Journal of Medicinal Chemistry. 41(19):3645-54, 1998 Sep.
48. Andronati, S., Sava, V., Makan, S., Kolodeev, G., Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors. Pharmazie. 54(2):99-101, 1999.
49. Song, J. J., Yee, N. K., A novel synthesis of 2-aryl-2H-indazoles via a palladium-catalyzed intramolecular amination reaction. Organic Letters. 2(4):519-21, 2000.
50. Isin, E. M., Jonge, M., Castagnoli, N. Jr., Studies on synthetic approaches to 1H- and 2H-indazolyl derivatives. Journal of Organic Chemistry. 66(12):4220-6, 2001.
51. Lee, F. Y., Lien, J, C., Huang, L. J., Huang, T. M., Tsai, S. C., Teng, C. M., Wu, C. C., Cheng, F. C., Kuo, S. C., Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)- indazole analogues as novel antiplatelet agents. Journal of Medicinal Chemistry. 44(22):3746-9, 2001.
52. Yoshina, S., Tanaka, A., Kuo, S. C., Studies on heterocyclic compounds. XXXIII. Synthesis of furo[3,2-C]-pyrazole derivatives. (1). Synthetic investigation of furo[3,2-C]-pyrazoles (author's transl). Yakugaku Zasshi - Journal of the Pharmaceutical Society of Japan. 97(9):955-61, 1977 Sep.
53. 李芳裕，3-(5'-羥甲基-2'-呋喃基)-1-苯甲基吲唑類緣化合物之合成及其抗血小板活性，中國醫藥學院博士論文，1997。
54. New, D. R. Harvey, R.O.C. Norman, Journal of chemistry society.,4860,1964.
55. O'Brien, J. R., Platelet aggregation II. Some results from a new method of study. Journal of Clinical Pathology. 15:452-55, 1962.
56. Teng, C. M., Chen, W. Y., Ko, W. C., Ouyang, C., Antiplatelet effects of butylidenephthalide. Biochemistry and Biophysics Acta., 924:375-82, 1987.
57. Lopez-Lluch, G., Buron, M. I., Alcain, F. J., Quesada, J. M., Navas, P., Redox Regulation of cAMP Levels by Ascorbate in 1,25-Dihydroxy-vitamine D3-induced Differentication of HL-60 cells. Journal of Biochmistry., 331(Pt. 1):21-7, 1998.
58. He, Q., Jiang, D., A Novel Aminosteroid is Active for Proliferation Inhibition and Differentiation Induction of Human Acute Myeloid Leukemia HL-60 Cells. Leukemia Research., 23(4):369-72, 1999.
59. Berridge, M. V., Tan, A. S., Characterization of the Cellular Reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphentltetrazolium Bromide (MTT) : Subcellular Localization, Substrate Dependence and Involvement of Mitochondrial Electron Transport in MTT Reduction. Archives of Biochemistry and Biophysics., 303:474-82, 1993.